{'52WeekChange': -0.601487,
 'SandP52WeekChange': None,
 'address1': '108 Cannon Street',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 5.59,
 'askSize': 2900,
 'averageDailyVolume10Day': 336200,
 'averageVolume': 447849,
 'averageVolume10days': 336200,
 'beta': None,
 'beta3Year': None,
 'bid': 5.29,
 'bidSize': 800,
 'bookValue': 2.723,
 'category': None,
 'circulatingSupply': None,
 'city': 'London',
 'companyOfficers': [],
 'country': 'United Kingdom',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 5.46,
 'dayLow': 5.2,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.627,
 'enterpriseToRevenue': 119.815,
 'enterpriseValue': 301093856,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 6.3665714,
 'fiftyTwoWeekHigh': 17.48,
 'fiftyTwoWeekLow': 4.98,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 64997518,
 'forwardEps': -1.68,
 'forwardPE': -3.1607144,
 'fromCurrency': None,
 'fullTimeEmployees': 252,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.13463001,
 'heldPercentInstitutions': 0.73710996,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/orchard-tx.com',
 'longBusinessSummary': 'Orchard Therapeutics plc, a biopharmaceutical '
                        'company, develops gene therapies for serious and '
                        'life-threatening rare diseases in the United Kingdom, '
                        "European Union, and the United States. The company's "
                        "gene therapy approach seeks to transform a patient's "
                        'hematopoietic stem cells into a gene-modified drug '
                        "product to treat the patient's disease through a "
                        'single administration. It provides Strimvelis, a '
                        'gammaretroviral-based product for the treatment of '
                        'adenosine deaminase-severe combined immunodeficiency '
                        "(ADA-SCID). The company's clinical development "
                        'products comprise OTL-101 for the treatment of '
                        'ADA-SCID; OTL-200 to treat metachromatic '
                        'leukodystrophy; OTL-103 for the treatment of '
                        'Wiskott-Aldrich syndrome; OTL-102 for X-linked '
                        'chronic granulomatous disease; and OTL-300 for '
                        'transfusion-dependent beta-thalassemia. Its '
                        'preclinical programs include OTL-201 for '
                        'mucopolysaccharidosis type MPS-IIIA and OTL-202 for '
                        'mucopolysaccharidosis type IIIB. Orchard Therapeutics '
                        'plc entered into a manufacturing and technology '
                        'development agreement with MolMed S.p.A. to develop, '
                        'manufacture and supply certain viral vectors and '
                        'conduct cell processing activities for certain '
                        'Orchard development and commercial programs. The '
                        'company was formerly known as Orchard Rx Limited. '
                        'Orchard Therapeutics plc was founded in 2015 and is '
                        'based in London, the United Kingdom.',
 'longName': 'Orchard Therapeutics plc',
 'market': 'us_market',
 'marketCap': 516470784,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_334227332',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -183252000,
 'nextFiscalYearEnd': 1640908800,
 'open': 5.38,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '44 20 3384 6700',
 'previousClose': 5.36,
 'priceHint': 2,
 'priceToBook': 1.950055,
 'priceToSalesTrailing12Months': 205.5196,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 5.46,
 'regularMarketDayLow': 5.2,
 'regularMarketOpen': 5.38,
 'regularMarketPreviousClose': 5.36,
 'regularMarketPrice': 5.38,
 'regularMarketVolume': 287883,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 97263800,
 'sharesPercentSharesOut': 0.022,
 'sharesShort': 1754439,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1193026,
 'shortName': 'Orchard Therapeutics plc',
 'shortPercentOfFloat': None,
 'shortRatio': 4.1,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'ORTX',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.906,
 'twoHundredDayAverage': 9.666547,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '52e7dcb9-b744-3324-bdb7-d4182ec897c5',
 'volume': 287883,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.orchard-tx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': 'EC4N 6EU'}